Table 5.
Matrix effects for spironolactone, 7-alpha-methylthiospironolactone, canrenone, and IS
| Concentration | Matrix | MF (%) | IS normalized MF (%) | |||||
|---|---|---|---|---|---|---|---|---|
| Spironolactone | 7-Alpha-methylthiospironolactone | Canrenone | IS | Spironolactone | 7-Alpha-methylthiospironolactone | Canrenone | ||
| Low, 3 ng/ml | Matrix 1 | 58.2% | 74.2% | 72.8% | 56.9% | 102.3% | 130.4% | 128.1% |
| Matrix 2 | 58.3% | 75.7% | 72.2% | 57.9% | 100.7% | 130.7% | 124.8% | |
| Matrix 3 | 57.3% | 73.9% | 70.5% | 58.2% | 98.3% | 126.8% | 121.0% | |
| Matrix 4 | 57.0% | 69.9% | 70.2% | 57.9% | 98.3% | 120.7% | 121.2% | |
| Matrix 5 | 60.2% | 67.6% | 69.2% | 61.0% | 98.6% | 110.9% | 113.5% | |
| Matrix 6 | 59.2% | 71.6% | 68.8% | 59.8% | 99.0% | 119.6% | 114.9% | |
| CV% | 2.1% | 4.2% | 2.3% | 2.6% | 1.6% | 6.2% | 4.7% | |
| High, 200 ng/ml | Matrix 1 | 64.8% | 73.1% | 79.5% | 64.6% | 100.4% | 113.2% | 123.1% |
| Matrix 2 | 66.7% | 69.3% | 77.6% | 65.8% | 101.3% | 105.3% | 117.9% | |
| Matrix 3 | 67.4% | 67.4% | 77.1% | 68.8% | 98.0% | 98.0% | 112.1% | |
| Matrix 4 | 66.1% | 66.3% | 72.7% | 67.9% | 97.3% | 97.6% | 106.9% | |
| Matrix 5 | 66.7% | 68.4% | 72.9% | 67.2% | 99.2% | 101.8% | 108.6% | |
| Matrix 6 | 67.1% | 68.4% | 77.1% | 67.3% | 99.7% | 101.7% | 114.5% | |
| CV% | 1.4% | 3.4% | 3.6% | 2.3% | 1.5% | 5.6% | 5.3% | |